RNA-seq analysis of the transcriptomic profiles of ATO+DAC-treated THP-1 cell lines expressing p53-R282W, vector control, or p53-R282W with IRF7 knockdown. RNA-seq analysis of the transcriptomic profiles of ATO+DAC-treated THP-1 cell lines expressing p53-R282W, vector control, or p53-R282W with IRF7 knockdown

To investigate the transcriptomic effects of ATO and DAC co-treatment in THP-1 cells expressing different p53 contexts, RNA-seq analysis was conducted on cell lines expressing p53-R282W, vector control, or p53-R282W with IRF7 knockdown. Cells were treated with arsenic trioxide (1 μg/mL) and decitabine (5 μM) prior to total RNA extraction. Purified mRNA was subjected to high-throughput sequencing using the Illumina HiSeq platform. Sequencing reads that passed quality control were trimmed using Cutadapt and used for downstream transcriptomic analysis. Overall design: RNA-seq was performed to evaluate transcriptional activity of mutant p53 in response to the indicated treatments.

为探究三氧化二砷（arsenic trioxide, ATO）与地西他滨（decitabine, DAC）联合处理对携带不同p53遗传背景的THP-1细胞的转录组学效应，本研究针对分别表达p53-R282W、空载体对照，或经干扰素调节因子7（Interferon Regulatory Factor 7, IRF7）敲低的p53-R282W的细胞系，开展了RNA测序（RNA sequencing, RNA-seq）分析。在提取总RNA前，先以1 μg/mL浓度的三氧化二砷与5 μM浓度的地西他滨处理细胞。将纯化得到的mRNA采用Illumina HiSeq平台进行高通量测序。通过质量控制的测序读段经Cutadapt软件进行序列修剪后，用于后续转录组学分析。实验整体设计：通过RNA测序评估突变型p53在指定处理条件下的转录活性。